RegulatoryNov 6, 2026, 04:26 PM
POMDOCTOR Ltd Regains Nasdaq Bid Price Compliance; Hearing Cancelled
AI Summary
POMDOCTOR LIMITED announced it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). The company received written notification from Nasdaq on November 5, 2026, confirming compliance. Consequently, the previously scheduled hearing before the Nasdaq Hearings Panel on November 12, 2026, has been cancelled, and the company's securities will continue to be listed on the Nasdaq Global Market.
Key Highlights
- POMDOCTOR LIMITED regained compliance with Nasdaq minimum bid price requirement.
- Company received written notification from Nasdaq on November 5, 2026.
- Hearing before Nasdaq Hearings Panel scheduled for November 12, 2026 has been cancelled.
- Company's securities will continue to be listed and traded on the Nasdaq Global Market.
Price Impact
More from POM
DelistingNov 2, 4:32 PM
POMDOCTOR Receives Nasdaq Delisting Warnings for MVLS and MVPHS Deficiencies
Business UpdateSep 24, 9:05 AM
POMDOCTOR Highlights Differentiated 'Hardware + AI + Payment' Healthcare Model
Business UpdateAug 10, 8:11 AM
Pomdoctor Highlights Healthcare Intelligence Flywheel as Growth Engine